AIDS - Related Cancer Pipeline Review, H2 2012


#146070

130pages

Global Markets Direct

$ 2000

In Stock


AIDS Related Cancer Pipeline Review, H2 2012

Global Markets Directs, 'AIDS Related Cancer Pipeline Review, H2 2012', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for AIDS Related Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for AIDS Related Cancer. AIDS Related Cancer Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • A snapshot of the global therapeutic scenario for AIDS Related Cancer.
  • A review of the AIDS Related Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • Coverage of products based on various stages of development ranging from discovery till registration stages.
  • A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
  • Coverage of the AIDS Related Cancer pipeline on the basis of route of administration and molecule type.
  • Key discontinued pipeline projects.
  • Latest news and deals relating to the products.

Reasons to buy
  • Identify and understand important and diverse types of therapeutics under development for AIDS Related Cancer.
  • Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
  • Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
  • Devise corrective measures for pipeline projects by understanding AIDS Related Cancer pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Table of Contents

Table of Contents 2

List of Tables 7
List of Figures 8
Introduction 9
Global Markets Direct Report Coverage 9
AIDS - Related Cancer Overview 10
Therapeutics Development 11
An Overview of Pipeline Products for AIDS - Related Cancer 11
AIDS - Related Cancer Therapeutics under Development by Companies 13
AIDS - Related Cancer Therapeutics under Investigation by Universities/Institutes 14
Mid Clinical Stage Products 17
Comparative Analysis 17
Early Clinical Stage Products 18
Comparative Analysis 18
Discovery and Pre-Clinical Stage Products 19
Comparative Analysis 19
AIDS - Related Cancer Therapeutics Products under Development by Companies 20
AIDS - Related Cancer Therapeutics Products under Investigation by Universities/Institutes 21
Companies Involved in AIDS - Related Cancer Therapeutics Development 24
Amorfix Life Sciences Ltd. 24
Aphios Corporation 25
Azaya Therapeutics, Inc. 26
PTC Therapeutics, Inc. 27
AIDS - Related Cancer Therapeutics Assessment 28
Assessment by Monotherapy Products 28
Assessment by Combination Products 29
Assessment by Route of Administration 30
Assessment by Molecule Type 32
Drug Profiles 34
Dermos - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
PTC-299 - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
Doxil + Methotrexate + Prednisone + Vincristine Sulfate + Sargramostim - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
sirolimus - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
bevacizumab - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
Cetuximab + Fluoroucacil + Cisplatin + Radiation Therapy - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
imatinib - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
semaxanib - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
cART + R-EPOCH - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 46
CHOP-BLEO + Radiation Therapy - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 48
FLEP + Radiation Therapy - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
ASHAP + IMVP16 + Radiation Therapy - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 53
G-CSF + Cyclophosphamide + Etoposide + Lomustine + Procarbazine + Radiation Therapy - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 56
bortezomib - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
lenalidomide - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
Methotrexate + Zidovudine + Radiation Therapy - Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
halofuginone hydrobromide - Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
Filgrastim + Cyclophosphamide + Cytarabine + Methotrexate + Pegylated Liposomal Doxorubicin Hydrochloride + Prednisone + Vincristine Sulfate + Radiation Therapy - Drug Profile 62
Product Description 62
Mechanism of Action 62
R&D Progress 63
MEAM + HAART + Stem Cell Transplantation - Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 66
BCNU + Etoposide + Cytarabine + Melphalan + Autologous Hematopoietic Cell Transplantation - Drug Profile 67
Product Description 67
Mechanism of Action 67
R&D Progress 67
Interferon beta-1b + Zidovudine - Drug Profile 69
Product Description 69
Mechanism of Action 69
R&D Progress 69
EPOCH Regimen + Methotrexate + Prednisone + Cytarabine + Filgrastim - Drug Profile 70
Product Description 70
Mechanism of Action 71
R&D Progress 72
EPOCH Regimen + Methotrexate + Prednisone + Cytarabine + Filgrastim - Drug Profile 74
Product Description 74
Mechanism of Action 75
R&D Progress 76
Filgrastim + Pegfilgrastim + Rituximab + Cyclophosphamide + Cytarabine + Doxorubicin Hydrochloride + Etoposide + Ifosfamide + Leucovorin Calcium + Liposomal Cytarabine + Methotrexate + Therapeutic Hydrocortisone + Vincristine Sulfate - Drug Profile 78
Product Description 78
Mechanism of Action 79
R&D Progress 80
Fludarabine Phosphate + Total-Body Irradiation + Peripheral Blood Stem Cell Transplantation + Cyclosporine + Mycophenolate Mofetil - Drug Profile 82
Product Description 82
Mechanism of Action 82
R&D Progress 83
lenalidomide - Drug Profile 84
Product Description 84
Mechanism of Action 84
R&D Progress 84
R-EPOCH + cART - Drug Profile 85
Product Description 85
Mechanism of Action 85
R&D Progress 86
sunitinib malate - Drug Profile 87
Product Description 87
Mechanism of Action 87
R&D Progress 87
G-CSF + Cyclophosphamide + Etoposide + Lomustine + Procarbazine - Drug Profile 88
Product Description 88
Mechanism of Action 88
R&D Progress 88
G-CSF + Cyclophosphamide + Etoposide + Lomustine + Procarbazine Hydrochloride + Radiation Therapy - Drug Profile 90
Product Description 90
Mechanism of Action 90
R&D Progress 91
ProMACE-CytaBOM + TMP-SMX + G-CSF + Radiation therapy - Drug Profile 92
Product Description 92
Mechanism of Action 93
R&D Progress 94
bleomycin sulfate - Drug Profile 96
Product Description 96
Mechanism of Action 96
R&D Progress 96
Filgrastim + Rituximab + Sargramostim + Cyclophosphamide + Doxil + Prednisone + Vincristine Sulfate - Drug Profile 97
Product Description 97
Mechanism of Action 97
R&D Progress 98
Rituximab + EPOCH - Drug Profile 99
Product Description 99
Mechanism of Action 99
R&D Progress 100
Rituximab + EPOCH + Vorinostat - Drug Profile 101
Product Description 101
Mechanism of Action 101
R&D Progress 102
R-CHOP - Drug Profile 103
Product Description 103
Mechanism of Action 103
R&D Progress 103
R-CHOP + Vorinostat - Drug Profile 105
Product Description 105
Mechanism of Action 105
R&D Progress 106
Etoposide + Methylprednisolone Sodium Succinate + Carboplatin + AraC + Rituximab + MCNU + L-PAM + Autologous Peripheral Blood Stem Cell Transplantation - Drug Profile 107
Product Description 107
Mechanism of Action 107
R&D Progress 108
HAART + Bevacizumab - Drug Profile 109
Product Description 109
Mechanism of Action 109
R&D Progress 110
CHOP + Rituximab + Peripheral Blood Stem Cell Transplantation - Drug Profile 111
Product Description 111
Mechanism of Action 111
R&D Progress 112
HAART + Methotrexate + Rituximab + Leucovorin - Drug Profile 113
Product Description 113
Mechanism of Action 113
R&D Progress 114
Velcade + Carboplatin + Dexamethasone + Etoposide + Ifosfamide - Drug Profile 115
Product Description 115
Mechanism of Action 115
R&D Progress 116
Fludarabine + Busulfan + Melphalan + Cyclophosphamide + Total Body Irradiation + Allogeneic Hematopoietic Cell Transplantation - Drug Profile 117
Product Description 117
Mechanism of Action 117
R&D Progress 118
doxorubicin - Drug Profile 119
Product Description 119
Mechanism of Action 119
R&D Progress 119
Anti-CD38 - Drug Profile 120
Product Description 120
Mechanism of Action 120
R&D Progress 120
AIDS - Related Cancer Therapeutics Drug Profile Updates 121
AIDS - Related Cancer Therapeutics Discontinued Products 122
AIDS - Related Cancer Therapeutics - Dormant Products 123
AIDS - Related Cancer Product Development Milestones 128
Featured News & Press Releases 128
Aug 05, 1997: Taxol Approved for Kaposi's Sarcoma 128

Appendix 129
Methodology 129
Coverage 129
Secondary Research 129
Primary Research 129
Expert Panel Validation 129
Contact Us 130
Disclaimer 130

Number of Products Under Development for AIDS - Related Cancer, H2 2012 11
Products under Development for AIDS - Related Cancer Comparative Analysis, H2 2012 12
Number of Products under Development by Companies, H2 2012 13
Number of Products under Investigation by Universities/Institutes, H2 2012 15
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..1) 16
Comparative Analysis by Mid Clinical Stage Development, H2 2012 17
Comparative Analysis by Early Clinical Stage Development, H2 2012 18
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2012 19
Products under Development by Companies, H2 2012 20
Products under Investigation by Universities/Institutes, H2 2012 21
Products under Investigation by Universities/Institutes, H2 2012 (Contd..1) 22
Products under Investigation by Universities/Institutes, H2 2012 (Contd..2) 23
Amorfix Life Sciences Ltd., H2 2012 24
Aphios Corporation, H2 2012 25
Azaya Therapeutics, Inc., H2 2012 26
PTC Therapeutics, Inc., H2 2012 27
Assessment by Monotherapy Products, H2 2012 28
Assessment by Combination Products, H2 2012 29
Assessment by Stage and Route of Administration, H2 2012 31
Assessment by Stage and Molecule Type, H2 2012 33
AIDS - Related Cancer Therapeutics Drug Profile Updates 121
AIDS - Related Cancer Therapeutics Discontinued Products 122
AIDS - Related Cancer Therapeutics Dormant Products 123
AIDS - Related Cancer Therapeutics Dormant Products (Contd..1) 124
AIDS - Related Cancer Therapeutics Dormant Products (Contd..2) 125
AIDS - Related Cancer Therapeutics Dormant Products (Contd..3) 126
AIDS - Related Cancer Therapeutics Dormant Products (Contd..4) 127
Number of Products under Development for AIDS - Related Cancer, H2 2012 11
Products under Development for AIDS - Related Cancer Comparative Analysis, H2 2012 12
Products under Development by Companies, H2 2012 13
Products under Investigation by Universities/Institutes, H2 2012 14
Mid Clinical Stage Products, H2 2012 17
Early Clinical Stage Products, H2 2012 18
Discovery and Pre-Clinical Stage Products, H2 2012 19
Assessment by Monotherapy Products, H2 2012 28
Assessment by Combination Products, H2 2012 29
Assessment by Route of Administration, H2 2012 30
Assessment by Stage and Route of Administration, H2 2012 31
Assessment by Molecule Type, H2 2012 32
Assessment by Stage and Molecule Type, H2 2012 33